Plural Hetero Atoms In The Tricyclo Ring System Patents (Class 514/291)
  • Patent number: 8975242
    Abstract: The present invention relates to novel tigecycline compositions with improved stability in both solid and solution states and processes for making these compositions. These compositions comprise tigecycline, a suitable carbohydrate, and an acid or buffer.
    Type: Grant
    Filed: January 21, 2011
    Date of Patent: March 10, 2015
    Assignee: Wyeth LLC
    Inventors: Mahdi B. Fawzi, Tianmin Zhu, Syed M. Shah
  • Publication number: 20150065499
    Abstract: The present invention relates to compounds according to Formula I: and salts thereof, wherein R1, R2, R3, R4, R5, R6, R7, X, and Y are as defined herein. Methods for preparing compounds of Formula I are also provided. The present invention further includes methods of treating cellular proliferative disorders, such as cancer, with the compounds of Formula I.
    Type: Application
    Filed: February 26, 2013
    Publication date: March 5, 2015
    Inventors: E. Premkumar Reddy, M. V. Ramana Reddy
  • Publication number: 20150065471
    Abstract: The present invention is directed to a pharmaceutically acceptable crystalline addition salt of 5-[(1R)-2-({2-[4-({4-(2,2-difluoro-2-phenylethoxy)phenyl]ethyl}amino)-1-hydroxyethyl]-8-hydroxyquinolin-2(1H)-one, and (ii) a dicarboxylic acid, a sulfonic acid or a sulfimide, or a pharmaceutically acceptable solvate thereof.
    Type: Application
    Filed: March 28, 2013
    Publication date: March 5, 2015
    Inventors: Carlos Puig Duran, Francesc Carrera Carrera, Juan Bautista Pérez Garcia, Enrique Moyes Valles, Iolanda Marchueta Hereu
  • Publication number: 20150059746
    Abstract: A method is disclosed for making a pharmaceutical composition for pulmonary administration, the method comprising a step in which an inhalable pharmaceutically active material is acoustically blended in a resonant acoustic blender. The invention also relates to compositions for inhalation prepared by the method.
    Type: Application
    Filed: March 28, 2013
    Publication date: March 5, 2015
    Inventor: Matthew Green
  • Patent number: 8968763
    Abstract: Disclosed herein are implantable medical devices comprising controlled release biodegradable block copolymers or coated with controlled release block copolymers and at least one drug releasable from the block copolymer. The controlled release block copolymers comprise least two blocks selected from the group consisting of polyesters, polyethers, and polyurethanes.
    Type: Grant
    Filed: February 19, 2010
    Date of Patent: March 3, 2015
    Assignee: Medtronic Vascular, Inc.
    Inventors: Ya Guo, Peiwen Cheng
  • Patent number: 8969373
    Abstract: A compound of general formula (I); A is O, S, CH, NH or NR?, when O links with Z3, Z1 is N or CRZ1, Z2 is CRZ2, when Z1 links with O, Z2 is CH, Z3 is C—Ar; Ra, Rb, Rc and Rd independently is H, OH, halogen or —Y1—Rm; A1 is NH or CH2; R1? is alkyl, aryl, cycloalkyl, heterocycloalkyl or heteroaryl; A2 is N, O or linking bond; R1 is hydrogen, or, R1 linking covalently with R3 forms C5-C9 saturated or unsaturated hydrocarbon chain substituted by O or N; R3 is alkyl, cycloalkyl, heterocycloalkyl, alkyl substituted by cycloalkyl etc; R4 is alkoxy-CO, alkyl-NHCO, (alkyl)2NCO, or formyl substituted by aryl, cycloalkyl, heterocycloalkyl.
    Type: Grant
    Filed: July 23, 2012
    Date of Patent: March 3, 2015
    Assignee: Shanghai Tangrun Pharmaceuticals Co., Ltd.
    Inventor: Suoming Zhang
  • Publication number: 20150057306
    Abstract: Described are compositions and methods for administering scopolamine and ketamine in the treatment of depression (e.g., Major Depressive Disorder and Treatment-Resistant Depression).
    Type: Application
    Filed: March 29, 2013
    Publication date: February 26, 2015
    Inventors: Maurizio Fava, Tracey Petryshen
  • Publication number: 20150056265
    Abstract: A coating composition for drug-eluting medical devices, which enables a medical device to be delivered to a target tissue for the purpose of treating an affected blood vessel part such as restenosis, without easy separation of a drug from the medical device during the delivery process is provided. The coating composition for drug-eluting medical devices contains a water-insoluble drug and at least one selected from the group consisting of ester compounds of amino acids, which have a hydropathy index of the amino acid of zero or less than zero, and salts thereof. A drug coating layer, a drug-eluting medical device and a method of treatment are also provided.
    Type: Application
    Filed: September 25, 2014
    Publication date: February 26, 2015
    Applicant: TERUMO KABUSHIKI KAISHA
    Inventors: Keiko YAMASHITA, Shigenori NOZAWA
  • Publication number: 20150057746
    Abstract: A coating composition for drug eluting medical devices, which is capable of forming a drug coating layer that is not susceptible to peeling during delivery to a target tissue is provided. This coating composition contains: a water-insoluble drug; at least one selected from the group consisting of hyaluronic acid, alkanoyl hyaluronic acids obtained by substituting at least part of hydrogen atoms in the hydroxyl groups of hyaluronic acid with an alkanoyl group, and salts of hyaluronic acid and the alkanoyl hyaluronic acids; and at least one selected from the group consisting of amino-acid esters and salts thereof. A drug coating layer, a medical device and a method of treatment are also provided.
    Type: Application
    Filed: September 25, 2014
    Publication date: February 26, 2015
    Applicant: TERUMO KABUSHIKI KAISHA
    Inventors: Keiko YAMASHITA, Shigenori NOZAWA, Masashi ISOZAKI
  • Publication number: 20150057233
    Abstract: The present invention relates to a calcineurin inhibitor for use in the treatment of a lesional vestibular disorder.
    Type: Application
    Filed: February 22, 2013
    Publication date: February 26, 2015
    Inventor: Jonas Dyhrfjeld-Johnsen
  • Patent number: 8962648
    Abstract: Tricyclic compounds are provided. These compounds are PBK inhibitors, and are useful for the treatment of PBK related diseases, including cancer.
    Type: Grant
    Filed: March 29, 2011
    Date of Patent: February 24, 2015
    Assignee: OncoTherapy Science, Inc.
    Inventors: Yusuke Nakamura, Yo Matsuo, Shoji Hisada, Feryan Ahmed, Raymond Huntley, Zohreh Sajjadi-Hashemi, David M. Jenkins, Robert B. Kargbo, Wenge Cui, Polivina Jolicia F. Gauuan, Joel R. Walker, Helene Decornez, Mahender Gurram
  • Publication number: 20150051207
    Abstract: The present invention is directed to unsaturated sphingosine compounds which are useful as therapeutic agents for the treatment of cancer and for the treatment of other diseases including diabetes and infection with intracellular bacteria. The invention is also directed to methods of using the compounds and pharmaceutical compositions comprising the compounds in treating these diseases.
    Type: Application
    Filed: April 24, 2014
    Publication date: February 19, 2015
    Inventors: Julie D. Saba, Henrik Fyrst, Robert Bittman
  • Publication number: 20150050356
    Abstract: The present invention features methods for treating, stabilizing, preventing, and/or delaying cancer by administering nanoparticles that comprise rapamycin or a derivative thereof. The invention also provides compositions (e.g., unit dosage forms) comprising nanoparticles that comprise a carrier protein and rapamycin or a derivative thereof. The invention further provides combination therapy methods of treating cancer comprising administering to an individual an effective amount of nanoparticles that comprise rapamycin or a derivative thereof and a second therapy.
    Type: Application
    Filed: October 28, 2014
    Publication date: February 19, 2015
    Inventors: Neil P. DESAI, Patrick SOON-SHIONG, Vuong TRIEU
  • Publication number: 20150051241
    Abstract: The present invention relates to a novel form of anhydrous tiotropium bromide, processes for the preparation of anhydrous tiotropium bromide, pharmaceutical compositions comprising anhydrous tiotropium bromide and uses of the compositions.
    Type: Application
    Filed: April 7, 2014
    Publication date: February 19, 2015
    Applicant: GENERICS [UK] LIMITED
    Inventors: Vinayak Govind GORE, Bindu MANOJKUMAR, Dattatraya SHINDE, Dattatrey KOKANE
  • Publication number: 20150050239
    Abstract: The present invention provides novel substituted pyrazolone compounds, pharmaceutical acceptable salts and formulations thereof useful in modulating the protein tyrosine kinase activity, and in modulating cellular activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.
    Type: Application
    Filed: July 19, 2013
    Publication date: February 19, 2015
    Applicants: Calitor Sciences, LLC, Sunshine Lake Pharma Co., Ltd.
    Inventors: Ning Xi, Yanjun Wu, Min Liao, Yanming Feng
  • Patent number: 8957209
    Abstract: The present invention relates to methods for synthesizing tiotropium bromide following the scheme: Using the above scheme, tiotropium bromide (compound 5A) is obtained under mild conditions and with high yields.
    Type: Grant
    Filed: October 1, 2012
    Date of Patent: February 17, 2015
    Inventor: Mahmut Bilgic
  • Publication number: 20150045418
    Abstract: This document provides methods and materials for treating cancers including renal cancer (e.g., renal cell carcinoma) as well as ovarian, breast, prostate, colon, pancreatic, bladder, liver, lung, and thyroid cancers and melanoma. For example, methods and material for using one or more inhibitors of an SCD1 polypeptide to treat renal cell carcinoma (e.g., clear cell renal cell carcinoma (ccRCC)) or to increase the efficacy of a renal cell carcinoma treatment are provided. In addition, this document provides methods and materials for using elevated SCD1 expression levels in diseased tissues as an indication that an SCD1 inhibitor can be used as an appropriate therapeutic to ameliorate the disease.
    Type: Application
    Filed: March 7, 2013
    Publication date: February 12, 2015
    Inventors: John A. Copland, III, Laura Ann Marlow, Christina Von Roemeling
  • Publication number: 20150044269
    Abstract: The present invention includes biocompatible polymeric coatings, membranes, matrices, and films to be used with implantable medical devices. Medical devices containing such materials applied to a surface thereof contain a film-forming fluorous homo-polymer or copolymer containing the polymerized residue of a fluorous moiety, wherein the relative amounts of the polymerized residues of one or more moieties are effective to provide the coating and films with properties effective for use in coating implantable med devices.
    Type: Application
    Filed: October 27, 2014
    Publication date: February 12, 2015
    Inventor: Jonathon Z. ZHAO
  • Publication number: 20150045374
    Abstract: The invention provides compounds and salts thereof as d herein. The invention also provides pharmaceutical compositions comprising a compound disclosed herein, processes for preparing compounds disclosed herein, intermediates useful for preparing compounds disclosed herein and therapeutic methods for treating an HIV infection, treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS or ARC symptoms in a mammal using compounds disclosed herein.
    Type: Application
    Filed: January 3, 2013
    Publication date: February 12, 2015
    Inventors: Kerim Babaoglu, Kyla L. Bjornson, Paul Hrvatin, Eric Lansdon, John O. Link, Hongtao Liu, Ryan McFadden, Michael L. Mitchell, Yingmei Qi, Paul A. Roethle, Lianhong Xu
  • Publication number: 20150044268
    Abstract: The present invention includes biocompatible polymeric coatings, membranes, matrices, and films to be used with implantable medical devices. Medical devices containing such materials applied to a surface thereof contain a film-forming fluorous homo-polymer or copolymer containing the polymerized residue of a fluorous moiety, wherein the relative amounts of the polymerized residues of one or more moieties are effective to provide the coating and films with properties effective for use in coating implantable med devices.
    Type: Application
    Filed: October 27, 2014
    Publication date: February 12, 2015
    Inventor: Jonathon Z. Zhao
  • Patent number: 8952033
    Abstract: Disclosed herein are novel 4-anilinofuro[2,3-b]quinoline derivatives of formula (I): or a pharmaceutically acceptable salt thereof, wherein each of the substituents is given the definition as set forth in the Specification and Claims. Also disclosed are the preparation processes of these derivatives and their uses in the manufacture of pharmaceutical compositions and in the treatment of cancers.
    Type: Grant
    Filed: December 30, 2011
    Date of Patent: February 10, 2015
    Assignee: Kaohsiung Medical University
    Inventors: Cherng-Chyi Tzeng, Yeh-Long Chen, Yu-Wen Chen, Pei-Jung Lu
  • Publication number: 20150038464
    Abstract: Disclosed herein are methods of increasing retinal responsiveness to light in a subject, such as a subject with retinal degeneration. The disclosed methods include administering one or more compounds that decrease or inhibit ?-aminobutyric acid (GABA) signaling to a subject with retinal degeneration. In some embodiments, the methods include selecting a subject with retinal degeneration and administering a ?-aminobutyric acid C (GABAC) receptor antagonist to the subject. In one example, the GABAC receptor antagonist is (1,2,5,6-tetrahydropyridin-4-yl)methylphosphinic acid (TPMPA). In other embodiments, the methods include selecting a subject with retinal degeneration and administering a metabotropic glutamate receptor (mGluR) antagonist to the subject. In one example, the mGluR antagonist is a mGlu1 receptor antagonist (for example, JNJ16259685).
    Type: Application
    Filed: May 17, 2012
    Publication date: February 5, 2015
    Applicant: The United States Government as represented by the Department of Veterans Affairs
    Inventor: Ralph J. Jensen
  • Publication number: 20150037280
    Abstract: The present invention provides novel substituted pyrazolone compounds, pharmaceutical acceptable salts and formulations thereof useful in modulating the protein tyrosine kinase activity, and in modulating cellular activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.
    Type: Application
    Filed: July 19, 2013
    Publication date: February 5, 2015
    Applicants: Sunshine Lake Pharma Co., Ltd., Calitor Sciences, LLC
    Inventors: Ning Xi, Yanjun Wu, Min Liao, Yanming Feng
  • Publication number: 20150037377
    Abstract: The present invention relates to substituted cellulose acetates and methods of use thereof. One embodiment of the present invention provides a coating having a substituted cellulose acetate having a polar substituent that has an oxygen atom covalently bonded to a nonmetal selected from the group of sulfur, phosphorus, and boron; wherein the nonmetal is present in at least about 0.01% by weight of the substituted cellulose acetate.
    Type: Application
    Filed: October 16, 2014
    Publication date: February 5, 2015
    Applicant: Celanese Acetate LLC
    Inventors: Michael T. Combs, Thomas S. Garrett
  • Patent number: 8946256
    Abstract: Compositions and methods are disclosed for treating vitiligo and promoting the formation of collagen.
    Type: Grant
    Filed: December 4, 2012
    Date of Patent: February 3, 2015
    Assignee: Biocosmeceuticals, LLC
    Inventor: Sarah Bacus
  • Patent number: 8946274
    Abstract: Methods of improving skin quality are disclosed. Generally, the methods include topically administering an IRM compound to a treatment area of skin for a period of time and in an amount effective for improving the quality of the skin. Suitable IRM compound compounds include agonists of one or more TLRs.
    Type: Grant
    Filed: September 10, 2012
    Date of Patent: February 3, 2015
    Assignee: Medicis Pharmaceutical Corporation
    Inventors: Richard L. Miller, James H. Lee, Mary L. Owens
  • Patent number: 8946260
    Abstract: The present invention provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4, R5, R6, A and n are as defined herein. A deuteriated derivative of the compound of Formula (I) is also provided.
    Type: Grant
    Filed: September 14, 2011
    Date of Patent: February 3, 2015
    Assignee: Novartis AG
    Inventors: Mark Gary Bock, Christoph Gaul, Venkateshwar Rao Gummadi, Henrik Moebitz, Saumitra Sengupta
  • Publication number: 20150031692
    Abstract: The present invention relates to new substituted pyrano and furanoquinolines having a great affinity for sigma receptors, especially sigma-1 receptors, as well as to the process for the preparation thereof, to compositions comprising them, and to their use as medicaments.
    Type: Application
    Filed: January 24, 2013
    Publication date: January 29, 2015
    Inventors: José-Luis Diaz-Fernández, Ute Christmann
  • Publication number: 20150030654
    Abstract: An amorphous PDLLA stent coating for drug delivery is disclosed.
    Type: Application
    Filed: April 23, 2014
    Publication date: January 29, 2015
    Applicant: Advanced Cardiovascular Systems, Inc.
    Inventors: Wouter E. Roorda, Ni Ding
  • Publication number: 20150030652
    Abstract: A block copolymer comprising a fluorinated block and a non-fluorinated block and method of making the block copolymer are provided. Also provided herein are a coating on an implantable device comprising the block copolymer and method of using the implantable device.
    Type: Application
    Filed: October 3, 2014
    Publication date: January 29, 2015
    Inventor: Charles D. Claude
  • Publication number: 20150030587
    Abstract: Methods of treating a head and neck cancer are disclosed.
    Type: Application
    Filed: February 11, 2014
    Publication date: January 29, 2015
    Applicant: FOUNDATION MEDICINE, INC.
    Inventors: Chris Hendrik Boshoff, Timothy Robert Fenton, Matthias Alexander Lechner, Philip James Stephens, Matthew J. Hawryluk, Garrett Michael Frampton, Roman Yelensky
  • Patent number: 8940732
    Abstract: The invention relates to methods for diagnosis and treatment of autism spectrum disorders, particularly for autism spectrum disorders characterized by increased head size (circumference) and deficits in social behavior.
    Type: Grant
    Filed: January 15, 2010
    Date of Patent: January 27, 2015
    Assignee: Massachusetts Institute of Technology
    Inventors: Damon Theron Page, Mriganka Sur
  • Publication number: 20150025020
    Abstract: The present invention relates to a self-preserved oil dispersion. Especially, the present invention relates to a self-preserved oil dispersion including a dispersed oil phase, an aqueous phase and at least one surfactant, wherein said oil dispersion comprises boric acid in an amount ranging from 0.005% to 0.075% in weight of the total weight of the oil dispersion, said amount of boric acid being a preservative effective amount so that the oil dispersion has a preservative activity.
    Type: Application
    Filed: February 22, 2013
    Publication date: January 22, 2015
    Inventors: Jean-Sébastien Garrigue, Frédéric Lallemand, Betty Philips
  • Publication number: 20150025061
    Abstract: The present invention is directed to a method of enhancing visual acuity in a subject, comprising intravitreally administering to the subject in need of such enhancement, a therapeutically effective amount of an extrasynaptic GABAA receptor antagonist. The present invention is also directed to an ocular implant comprising a therapeutically effective amount of the extrasynaptic GABAA receptor antagonist.
    Type: Application
    Filed: July 10, 2014
    Publication date: January 22, 2015
    Inventor: Movses H. Karakossian
  • Publication number: 20150025067
    Abstract: Inhibitors of p67phox protein are provided herein, as well as pharmaceutical compositions and methods relating thereto.
    Type: Application
    Filed: February 13, 2013
    Publication date: January 22, 2015
    Applicant: CHILDREN'S HOSPITAL MEDICAL CENTER
    Inventors: Yi Zheng, Prakash Jagtap, Emily E. Bosco, Jaroslaw Meller, Marie-Dominique Filippi
  • Publication number: 20150017651
    Abstract: Methods and composition for tumor therapy, especially esophageal adenocarcinoma (EAC), are described. For example, in certain aspects methods for determining Hedgehog and mTOR signaling pathway status to select patients for administering a combination therapy of Hedgehog and mTOR signaling inhibitors are described. Furthermore, the invention provides compositions that involve testing kits for determining signaling status.
    Type: Application
    Filed: January 14, 2013
    Publication date: January 15, 2015
    Applicant: Board of Regents, The University of Texas System
    Inventors: Mien-Chie Hung, Yan Wang, Jaffer Ajani
  • Publication number: 20150018383
    Abstract: The present invention is directed to the use of marker for Akt2 activation in podocytes as a biomarker to predict toxicity of mTOR inhibitors. Another aspect of the invention relates to a method for preventing graft rejection comprising administering a selective mTORC1 or Akt1 inhibitor in a subject in need thereof.
    Type: Application
    Filed: October 12, 2012
    Publication date: January 15, 2015
    Applicant: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Fabiola Terzi, Guillaume Canaud, Franck Ename
  • Publication number: 20150018371
    Abstract: Positive allosteric modulators of melanocortin receptors, especially allosteric potentiators of the receptors MC3R and MC4R are described herein. Also provided are pharmaceutical compositions containing the positive allosteric modulators and methods of treating obesity or an obesity-related disorder such as type 2 diabetes, comprising administering an effective amount of the positive allosteric modulator.
    Type: Application
    Filed: March 6, 2013
    Publication date: January 15, 2015
    Inventors: Roger D. Cone, Julien A. Sebag, Jacques Pantel, Savannah Y. Williams, David C. Weaver, Gary A. Sulikowski, Craig W. Lindsley, Padma S. Portonova, Chao Zhang
  • Publication number: 20150018296
    Abstract: The present invention is directed to therapeutic methods and compositions involving cyclohexenone compounds where said compounds inhibit farnesyltransferase or Ras. The therapeutic methods (e.g. for treating cancers) comprise contacting a tumor with a cyclohexenone compound and an anticancer agent.
    Type: Application
    Filed: March 13, 2014
    Publication date: January 15, 2015
    Applicant: Golden Biotechnology Corporation
    Inventors: Sheng-Yung Liu, Wu-Che Wen, Chih-Ming Chen
  • Publication number: 20150011578
    Abstract: The present invention relates to methods for improving muscle strength and treating muscular dystrophy.
    Type: Application
    Filed: February 1, 2013
    Publication date: January 8, 2015
    Inventors: Samuel A. Wickline, Gregory M. Lanza
  • Publication number: 20150010636
    Abstract: A method for inhibiting formation of adhesions following abdominal surgery which involves application of an anti-static fatty acid ethoxylated amide (Cocamide DEA) in a matrix that is placed in the peritoneal cavity at the conclusion of an abdominal surgery and which releases this anti-adhesive chemical over a predetermined time in a range up to seven days. Tests conducted on laboratory rats established that the method reduced the incidence of adhesions from 100 percent (100%) in a test model to near zero in the majority of treated animals. In an alternative embodiment, andrographalide was delivered via a pump with similar results. In still another embodiment, an effective amount of 50% phosphatidylchorene and propylene glycol was delivered, via a pump, into the abdominal cavity, again with similar results.
    Type: Application
    Filed: September 10, 2014
    Publication date: January 8, 2015
    Applicant: ANHESE LLC
    Inventor: John P. Delaney
  • Publication number: 20150011521
    Abstract: A method of controlled in vivo drug delivery is provided. A porous silicon matrix having pores sized and configured to admit to trap and then release a predetermined molecular complex with a predetermined dose-time profile is selected. The matrix contains the predetermined molecular complex so that the predetermined molecular complex is disposed within the pores of the porous silicon matrix. The matrix is introduced into a human body. The drug releases according the dose-time profile. The introduction can be via transdermal introduction, intramuscular injection, intravenous introduction, surgical implantation, inhalation, and oral ingestion.
    Type: Application
    Filed: September 19, 2014
    Publication date: January 8, 2015
    Inventors: Michael J. Sailor, Guarav Abbi, Boycee E. Collins, Keiki-Pua S. Dancil
  • Publication number: 20150004154
    Abstract: The present invention relates to a method of suppressing organ rejection in a patient receiving an organ transplant by initiating oral treatment with a once-daily extended release tacrolimus dosage form, for example, at an initial dose of from about 0.15 to about 0.20 mg/kg/day within 24 or 48 hours following transplantation. The once-daily extended release tacrolimus dosage form (i) provides low fluctuation and/or swing of tacrolimus, (ii) provides a significantly lower Cmax than an immediate release formulation of tacrolimus while providing the same or greater area under the curve (AUC), (iii) releases the tacrolimus substantially in the colon and/or the lower ileum, (iv) releases at most 63.5% of the tacrolimus in the dosage form at the 12 hour time point, or (v) any combination of any of the foregoing.
    Type: Application
    Filed: June 27, 2014
    Publication date: January 1, 2015
    Inventor: William J. POLVINO
  • Publication number: 20150005338
    Abstract: The invention provides compounds having the formula: wherein R1 is halogen. The invention also provides compositions comprising the compounds, and methods of treating diseases or disorders that comprise administering one or more of the compounds to a subject in need thereof. The disclosed compounds have CCR1 antagonist activity.
    Type: Application
    Filed: February 4, 2014
    Publication date: January 1, 2015
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Kenneth G. Carson, Geraldine C.B. Harriman, Shomir Ghosh
  • Publication number: 20140378501
    Abstract: Provided are methods and compositions for the treatment of depression and anxiety. The compositions contain scopolamine, or an analog thereof, and can optionally include one or more psychoactive agents. Further provided is an inhaler containing scopolamine, or an analog thereof, in a pharmaceutically acceptable carrier.
    Type: Application
    Filed: September 5, 2014
    Publication date: December 25, 2014
    Applicant: The Governmen of the United States of America, as represented by Secretary, Department of Health and
    Inventors: Maura L. Furey, Wayne C. Drevets
  • Publication number: 20140378524
    Abstract: Disclosed are methods of treating viral infections or disorders of uncontrolled proliferation comprising, in one aspect, administering compounds that are phospholipase D inhibitors and/or Akt therapeutic agents. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Application
    Filed: December 11, 2013
    Publication date: December 25, 2014
    Inventors: H. Alex Brown, Craig W. Lindsley
  • Publication number: 20140378500
    Abstract: A method for identifying cancer patients that are likely to be responders or non-responders to a signal transduction pathway inhibitor is described.
    Type: Application
    Filed: February 1, 2013
    Publication date: December 25, 2014
    Applicant: 20/20 GENE SYSTEMS, INC.
    Inventors: Jonathan Cohen, Alexandrine Josephe Derrien-Colemyn, John Gillespie, Soon Sik Park
  • Publication number: 20140377332
    Abstract: Nano-constructs comprising nanoshells and methods of using the nano-constructs for treating or ameliorating a medical condition are provided.
    Type: Application
    Filed: November 21, 2013
    Publication date: December 25, 2014
    Inventors: Florian N. Ludwig, Stephen D. Pacetti, Syed F.A. Hossainy, Dariush Davalian
  • Publication number: 20140377285
    Abstract: The present invention provides for methods and pharmaceutical compositions for treating disorders using treatment regimens involving multiple agents. In one aspect, a method of treatment is provided resulting in reduced toxicity and/or synergistic effect by administration according to a described dosing schedule.
    Type: Application
    Filed: November 8, 2012
    Publication date: December 25, 2014
    Inventors: Yi Liu, Shunyou Wang, Matthew R. Janes, Lucy Lan, Pingda Ren, Christian Rommel
  • Publication number: 20140370072
    Abstract: Provided herein is a prohealing piezoelectric coating and the method of making and using the same.
    Type: Application
    Filed: September 3, 2014
    Publication date: December 18, 2014
    Inventors: Syed Faiyaz Ahmed Hossainy, Mikael Trollsas, Lothar Walter Kleiner